New drug combination for advanced neuroblastoma in children
Part of Cancer clinical trials.
This trial tests a new combination of medicines for children with high-risk neuroblastoma that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a confirmed diagnosis of neuroblastoma (a type of nerve cell cancer).
- Your child must be at least 6 years old when joining the study.
- Your child must have at least one tumor that can be measured with a scan (like a CT or MRI).
- Previous cancer treatments must have ended at least 4 weeks before joining, and any side effects should be mostly resolved.
- Your child's organs (like liver, kidneys, heart) must be working well enough, and your child should be able to care for themselves (ECOG score 0-2).
- A parent or guardian must sign a consent form agreeing to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding a vaccine to a substance called beta-glucan (which may help the immune system) and a growth factor drug called GM-CSF can help prevent high-risk neuroblastoma from coming back. You would receive these as an injection or IV. The study is for people whose cancer is in remission or has responded well to prior treatment.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial combines the immunotherapy drug dinutuximab beta with two different chemotherapy regimens to see if it works better for children with high-risk neuroblastoma that has spread. It may be an option for newly diagnosed patients who have not had cancer treatment before.
This trial tests combining two immune-boosting drugs (naxitamab and GM-CSF) with a vitamin-A derivative (isotretinoin) to keep high-risk neuroblastoma in remission after standard treatment. It aims to see if this maintenance treatment helps prevent the cancer from returning.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.